FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
227 letters match. Newest first.
-
DrugsSignature Formulations, LLC
FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.
High risk -
DrugsHTO Nevada, Inc. dba Kirkman
HTO Nevada dba Kirkman, an OTC drug contract manufacturer, was cited for CGMP violations including mislabeled reformulated drugs.
High risk -
DrugsFulijaya Manufacturing SDN. BHD.
Fulijaya Manufacturing in Malaysia failed CGMP (drug manufacturing rules) for OTC drugs, with missing lab data, flawed microbial tests, and weak stability data.
High risk -
DrugsTower Laboratories Ltd.
FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.
High risk -
DrugsLiquidCapsule Manufacturing, LLC
LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.
High risk -
DrugsPrivate Label Skin Care, Inc.
FDA warned Private Label Skin Care about poor quality oversight, continued sale of impurity-affected over-the-counter drugs, and missing drug listings.
High risk -
DrugsGuangdong Renhe Guozhuang Biotechnology Co., Ltd.
FDA warns Guangdong Renhe Guozhuang Biotechnology over CGMP failures in OTC drug manufacturing.
High risk -
DrugsSklar Personal Care Inc.
Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.
High risk -
DrugsShoplet
FDA warned Shoplet over website sales of unapproved, misbranded triclosan antiseptic lotion soaps.
Medium -
DrugsMedical Mega
FDA: Medical Mega sells unapproved triclosan antiseptic soaps as nonprescription drugs.
Medium -
DrugsSinsin Pharmaceutical Co., Ltd.
FDA warned Sinsin Pharmaceutical that two Korean topical pain relievers sold in the US are unapproved and misbranded drugs.
High risk -
DrugsDermaRite Industries, LLC
DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.
High risk -
DrugsAcme United Corporation
Acme United Corporation made antiseptic wipes with contaminated water and released sterile drugs without sterility testing.
High risk -
DrugsFoshan Yiying Hygiene Products Co., Ltd.
Foshan Yiying, a Chinese OTC drug maker, lacked finished-product testing, stability data and process validation; FDA has blocked its imports.
High risk -
DrugsGuangxi Yulin Pharmaceutical Group Co. Ltd.
FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.
High risk -
DrugsBRS Analytical Services, LLC
BRS Analytical Services, LLC made sterile OTC drugs in an unsuitable aseptic facility and recalled them over sterility assurance.
High risk -
DrugsCreative Essences, Inc.
FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.
High risk -
DrugsPersōn & Covey, Inc.
FDA cites Persōn & Covey for CGMP failures at its Glendale, CA drug plant and for selling unapproved Xerac AC and Drysol.
High risk -
DrugsMedia Networks Sydney Pty. Limited
FDA says Australia's Media Networks Sydney failed to answer drug records requests for OTC Combantrin Chocolate Squares.
High risk -
DrugsYangzhou Yulou Paper Products Co., Ltd.
FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.
High risk -
DrugsAnhui Hanbon Daily Chemical Co., Ltd.
FDA warns Anhui Hanbon Daily Chemical over CGMP failures in OTC drugs, including use of an incorrect excipient and untested ingredients.
High risk -
DrugsEverlaan Organics, Inc. dba Maple Organics
FDA warns Maple Organics over OTC drug CGMP failures, unapproved new drugs, and misbranding.
High risk -
DrugsABBE Laboratories, Inc.
FDA warns ABBE Laboratories over manufacturing failures for over-the-counter topical drugs, including ingredient testing.
High risk -
DrugsGussyup LLC dba Private Label Grooming
FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.
High risk -
DrugsKabana Skin Care LLC
Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.
High risk -
DrugsDynamic Blending Specialists, Inc.
FDA cited Dynamic Blending Specialists for manufacturing failures in OTC drugs and an unapproved, misbranded oral antiseptic.
High risk -
DrugsHealwell Homeo Private Limited
FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.
High risk -
DrugsPushclean Technology Plastik Sanayi Ve Ticaret Ltd. Sirketi
FDA warns Turkish OTC drug wipe maker Pushclean over missing finished-product and component testing.
High risk -
DrugsKenil Healthcare Private Limited
FDA warns Kenil Healthcare over adulterated drugs from India due to cleaning, packaging, and quality failures.
High risk -
DrugsHorizon Tool Inc.
FDA warns Horizon Tool over manufacturing-rule violations for AllShield E2 Sanitizing Hand Soap.
High risk -
DrugsNefeteri Wellness
FDA says Nefeteri Wellness sells two unapproved colloidal silver vaginal gels promoted to treat infections.
High risk -
DrugsBio Wellness 444 LLC
Bio Wellness 444 sold Silver Bullet and Silver D douches as unapproved new drugs for vaginal infections.
High risk -
DrugsLaboratoire Druide Inc.
FDA warned Laboratoire Druide that its OTC drugs are adulterated because of inadequate glycerin identity testing, system validation and cleaning.
High risk -
DrugsAmish Origins Management, LLC
FDA warned Amish Origins over manufacturing quality failures and unapproved or misbranded OTC pain relief and lip balm products.
High risk -
DrugsCTK OTC Laboratories LLC formerly FMK LABS, Inc.
CTK OTC Laboratories, formerly FMK Labs, failed to investigate out-of-spec results and validate processes for OTC drugs, including sunscreens.
High risk -
DrugsEvi Labs LLC
FDA warns Evi Labs over OTC drug manufacturing failures, including an antiperspirant lot above the aluminum chlorohydrate limit.
High risk -
DrugsZhejiang Easyclean Daily Chemical Co., Ltd
FDA warned Zhejiang Easyclean Daily Chemical that its OTC drugs lacked required testing and manufacturing controls.
High risk -
DrugsHuangshi Hygienic Material Medicine Co., Ltd.
Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.
High risk -
DrugsProduct Society LLC
FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.
High risk -
DrugsTaizhou Jingshang Cosmetics Technology Co., Ltd.
FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.
High risk -
DrugsBioAsia Worldwide Sdn Bhd
FDA warned BioAsia Worldwide over current good manufacturing practice violations for OTC drugs.
High risk -
DrugsCosco International, Inc.
FDA warned Cosco International over nonprescription drug manufacturing failures and unapproved drug products.
High risk -
DrugsPMS4PMS, LLC
FDA warns PMS4PMS of Clarence, NY, over CGMP failures and an unapproved menstrual cramp relief cream.
High risk -
DrugsYangzhou Sion Commodity Co., Ltd.
FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.
High risk -
DrugsHangzhou Glamcos Biotech Co., Ltd.
Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.
High risk -
DrugsNeva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi
FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.
High risk -
DrugsAspen Pharmacare Holdings Limited
FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.
High risk -
DrugsLinghai ZhanWang Biotechnology Co., Ltd
Linghai ZhanWang Biotechnology's OTC drugs, including antimicrobial wipes, fail manufacturing quality rules; FDA cites missing tests.
High risk -
DrugsChem-Tech, Ltd.
Chem-Tech, Ltd. lacked adequate investigations and clean equipment for its OTC drug.
High risk -
DrugsMarshalls Traditional Healthcare CC
Marshalls Traditional Healthcare, an OTC drug maker in South Africa, lacked finished-product release testing and process validation.
High risk